CLDX
Celldex Therapeutics, Inc.
There isn't enough reported data to score CLDX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CLDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
CLDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CLDX PE Valuation
CLDX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CLDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CLDX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CLDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.65 | -$0.39 |
| Q2 2023 | -$2.41 | -$0.27 |
| Q1 2023 | -$2.53 | -$0.82 |
| Q4 2022 | -$2.40 | -$0.76 |
| Q3 2022 | -$2.26 | -$0.50 |
| Q2 2022 | -$2.14 | -$0.47 |
| Q1 2022 | -$1.71 | +$0.12 |
| Q4 2021 | -$1.64 | +$0.50 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 263% for CLDX versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
CLDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $22K | -97% |
| Q1 2026 | $15K | -98% |
| Q4 2025 | $121K | -90% |
| Q2 2025 | $730K | -71% |
| Q1 2025 | $695K | +346% |
| Q4 2024 | $1.2M | -72% |
| Q3 2024 | $3.2M | +110% |
| Q2 2024 | $2.5M | +832% |
CLDX's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -366468% | -357721 points |
| Q1 2026 | -562900% | -553873 points |
| Q4 2025 | -72027% | -67259 points |
| Q2 2025 | -8748% | -6893 points |
| Q1 2025 | -9027% | +17004 points |
| Q4 2024 | -4768% | -3615 points |
| Q3 2024 | -1634% | +1085 points |
| Q2 2024 | -1854% | +10536 points |
CLDX's operating margin was −366468% last quarter, down 357441 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CLDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CLDX on profitability, with a higher operating margin.
CLDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$66.7M | -$17.6M |
| Q2 2026 | -$60.6M | -$15.9M |
| Q1 2026 | -$67.2M | -$12.6M |
| Q4 2025 | -$65.2M | -$32M |
| Q3 2025 | -$49.1M | +$6.8M |
| Q2 2025 | -$44.7M | -$15.1M |
| Q1 2025 | -$54.6M | -$13.7M |
| Q4 2024 | -$33.2M | -$33K |
CLDX has burned cash in almost every quarter: −$260M over the past year, against −$182M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CLDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +691K shares |
| 1 year | +67% | +31.6M shares |
| 3 years | +351% | +61.1M shares |
CLDX has 79M diluted shares, up 67% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CLDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CLDX Net Leverage
CLDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CLDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 11.5 | Oversold |
CLDX's weekly RSI is 41 (neutral) and its Stochastic is 12 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CLDX PE vs Healthcare Sector
CLDX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CLDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.7 | 4.1% below |
| 20 week MA | $35.1 | 19% below |
| 50 week MA | $31.6 | 9.7% below |
| 100 week MA | $27.1 | 5.2% above |
| 200 week MA | $31.2 | 8.4% below |
CLDX's trend is mixed: it's above one of its five weekly moving averages, and 8.4% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CLDX on trend strength, trading above more of its moving averages.
CLDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.22 | $17.5 | +687% |
| 2021 | $17.5 | $42.0 | +140% |
| 2022 | $42.0 | $44.1 | +5% |
| 2023 | $44.1 | $39.7 | -10% |
| 2024 | $39.7 | $25.4 | -36% |
| 2025 | $25.4 | $26.4 | +4% |
| 2026 YTD | $26.4 | $28.5 | +8.1% |
CLDX has finished higher in four of the last six years, two of them by more than 50%. It's up 8.1% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CLDX on returns for 2026, with the stronger performance.